Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the bezafibrate infarction prevention study)

American Journal of Cardiology

Volumn 106, Issue 12, 2010, Pages 1717-1720

  Brodov, Yafim ^a   Behar, Shlomo ^a   Boyko, Valentina ^a   Chouraqui, Pierre ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; URIC ACID;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HEART DEATH; HUMAN; HYPERTENSION; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVENTION STUDY; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGED; BEZAFIBRATE; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERURICEMIA; HYPOLIPIDEMIC AGENTS; INCIDENCE; ISRAEL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRIGLYCERIDES; URIC ACID;

EID: 78649709694     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.07.046     Document Type: Article

References (30)

1. R.O. Bonow, and R.H. Eckel Diet, obesity, and cardiovascular risk N Engl J Med 348 2003 2057 2058
2. N. Sattar, A. Gaw, O. Scherbakova, I. Ford, D.S. O'Reilly, S.M. Haffner, C. Isles, P.W. Macfarlane, C.J. Packard, S.M. Cobbe, and J. Shepherd Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 108 2003 414 419
3. P.M. Ridker, P.W. Wilson, and S.M. Grundy Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109 2004 2818 2825
4. I. Holme, A.H. Aastveit, N. Hammar, I. Jungner, and G. Walldius Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS) J Intern Med 266 2009 558 570
5. C. Meisinger, W. Koenig, J. Baumert, and A. Dring Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study Arterioscler Thromb Vasc Biol 28 2008 1186 1192
6. Y. Brodov, P. Chouraqui, I. Goldenberg, V. Boyko, L. Mandelzweig, and S. Behar Serum uric acid for risk stratification of patients with coronary artery disease Cardiology 114 2009 300 305
7. D.I. Feig, D.H. Kang, and R.J. Johnson Uric acid and cardiovascular risk N Engl J Med 359 2008 1811 1821
8. M.I. Schmidt, B.B. Duncan, R.L. Watson, A.R. Sharrett, F.L. Brancati, and G. Heiss A metabolic syndrome in whites and African-Americans The Atherosclerosis Risk in Communities baseline study Diabetes Care 19 1996 414 418
9. L.V. Franse, M. Pahor, M. Di Bari, R.I. Shorr, J.Y. Wan, G.W. Somes, and W.B.J. Applegate Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) 18 J Hypertens 18 2000 1149 1154
10. M. Alderman Uric acid in hypertension and cardiovascular disease Can J Cardiol 15 suppl F 1999 20F 22F
11. A. Onat, H. Uyarel, G. Hergen, A. Karabulut, S. Albayrak, I. Sari, M. Yazici, and I. Kele Serum uric acid is a determinant of metabolic syndrome in a population-based study Am J Hypertens 19 2006 1055 1062
12. A.C. Gagliardi, M.H. Miname, and R.D. Santos Uric acid: A marker of increased cardiovascular risk Atherosclerosis 202 2009 11 17
13. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study Circulation 102 2000 21 27
14. N.N. Rehak, G. Janes, and D.S. Young Calorimetric enzymic measurement of uric acid in serum Clin Chem 23 1977 195 199
15. A.G. Fam Gout, diet, and the insulin resistance syndrome J Rheumatol 29 2002 1350 1355
16. A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, M.W. Steffes, R.J. Hogg, R.D. Perrone, J. Lau, G. Eknoyan National Kidney Foundation National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
17. A. Tenenbaum, M. Motro, E.Z. Fisman, D. Tanne, V. Boyko, and S. Behar Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome Arch Intern Med 165 2005 1154 1160
18. N. Nakanishi, M. Okamoto, H. Yoshida, Y. Matsuo, K. Suzuki, and K. Tatara Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers Eur J Epidemiol 18 2003 523 530
19. Y. Taniguchi, T. Hayashi, K. Tsumura, G. Endo, S. Fujii, and K. Okada Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey J Hypertens 19 2001 1209 1215
20. H. Vuorinen-Markkola, and H. Yki-Jrvinen Hyperuricemia and insulin resistance J Clin Endocrinol Metab 78 1994 25 29
21. A. Costa, I. Igual, J. Bedini, L. Quint, and I. Conget Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome Metabolism 51 2002 372 375
22. F. Matsuura, S. Yamashita, T. Nakamura, M. Nishida, S. Nozaki, T. Funahashi, and Y. Matsuzawa Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity Metabolism 47 1998 929 933
23. M.Y. Desai, D. Dalal, R.D. Santos, J.A. Carvalho, K. Nasir, and R.S. Blumenthal Association of body mass index, metabolic syndrome, and leukocyte count Am J Cardiol 97 2006 835 838
24. F. Facchini, Y.D. Chen, C.B. Hollenbeck, and G.M. Reaven Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration JAMA 266 1991 3008 3011
25. A. Coutinho Tde, S.T. Turner, P.A. Peyser, L.F. Bielak, P.F. Sheedy 2nd, and I.J. Kullo Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis Am J Hypertens 20 2007 83 89
26. C. Ruggiero, A. Cherubini, E. Miller 3rd, M. Maggio, S.S. Najjar, F. Lauretani, S. Bandinelli, U. Senin, and L. Ferrucci Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years Am J Cardiol 100 2007 115 121
27. R.D. Santos, K. Nasir, R. Orakzai, R.S. Meneghelo, J.A. Carvalho, and R.S. Blumenthal Relation of uric acid levels to presence of coronary artery calcium detected by electron beam tomography in men free of symptomatic myocardial ischemia with versus without the metabolic syndrome Am J Cardiol 99 2007 42 45
28. S.G. Tsouli, E.N. Liberopoulos, D.P. Mikhailidis, V.G. Athyros, and M.S. Elisaf Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 55 2006 1293 1301
29. L.C. See, C.F. Kuo, F.H. Chuang, H.Y. Li, Y.M. Chen, H.W. Chen, and K.H. Yu Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate J Rheumatol 36 2009 1691 1698
30. H.K. Choi, and G. Curhan Independent impact of gout on mortality and risk for coronary heart disease Circulation 116 2007 894 900